The Food and Drug Administration (FDA) will no longer require premarket review of laboratory developed tests (LDTs), including COVID-19 tests, decline to review emergency use authorization (EUA) request for LDTs. Instead, the FDA will prioritize review of EUAs for point-of-care tests, home collection tests, at-home tests, tests that reduce reliance on test supplies, and high-throughput, widely distributed tests.
FDA Will No Longer Review EUA Requests for COVID-19 Laboratory Developed Tests
More Issues
Wade’s Health Law Highlights for September 1, 2026
The Justice Department’s National Fraud Enforcement Division named healthcare one of five enforcement priorities, singling out telemedicine, Medicare and Medicaid billing, controlled substance diversion,…
Wade’s Health Law Highlights for August 25, 2026
The Fifth Circuit, sitting en banc, vacated the federal regulations governing how insurers calculate the qualifying payment amount under the No Surprises Act. In…
Wade’s Health Law Highlights for August 18, 2026
A Houston-area pharmacist was convicted of conspiracy to pay health care kickbacks after paying more than $2 million for patient referrals Tronown Thomas owned…